Retatrutide

Retatrutide (LY3437943) is a synthetic fatty-acid-modified peptide that simultaneously activates three receptors: the GLP-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). It represents the most advanced generation in incretin pharmacology research, extending the dual agonism approach pioneered by tirzepatide to encompass all three major receptors of the glucagon peptide family.

Molecular formula: C222H376N68O65S2 | Molecular weight: 4967.6 g/mol | CAS: 2381089-83-2 | Also known as: LY3437943 | Drug class: Triple incretin receptor agonist | Purity: greater than or equal to 98% as verified by HPLC | Form: Lyophilised powder | Appearance: White to off-white lyophilised powder | Storage: -20°C desiccated

The peptide backbone is derived from glucagon with sequence modifications achieving balanced agonism across all three receptors. A C18 fatty acid chain enables high-affinity non-covalent binding to serum albumin, extending the effective plasma half-life to approximately 6 days — suitable for chronic dosing paradigms in animal model research. Published characterisation by Coskun et al. (Cell Metabolism, 2022) established LY3437943 as a triple incretin receptor agonist tool compound.

Research applications include comparative receptor pharmacology studies examining GLP-1R, GIPR, and GCGR contributions to metabolic signalling, with Retatrutide serving as the triple agonist comparator alongside Semaglutide (GLP-1R monoagonist) and Tirzepatide (dual GLP-1R/GIPR). GCGR agonism adds hepatic glucose output, thermogenesis, and fatty acid oxidation research to the GLP-1R/GIPR metabolic profile.

Supplied as a lyophilised powder. Reconstitute with bacteriostatic water. Store at -20°C protected from light and moisture. For laboratory and analytical research purposes only. Not for human or veterinary use.